The robust immune response results enable Sanofi and GlaxoSmithKline to move to a late-stage study, the French drugmaker said.
Sanofi’s COVID-19 vaccine sees up to 100% efficacy in latest trial
© The Crystal Eyes
The robust immune response results enable Sanofi and GlaxoSmithKline to move to a late-stage study, the French drugmaker said.
© The Crystal Eyes